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ABSTRACT  
Acinic cell carcinoma (ACC) of the breast is a rare form of triple-negative (that is, estrogen 
receptor-negative, progesterone receptor-negative, HER2-negative) salivary gland-type 
tumor displaying serous acinar differentiation. Despite its triple-negative phenotype, breast 
ACCs are reported to have an indolent clinical behavior. Here, we sought to define whether 
ACCs have a mutational repertoire distinct from that of other triple-negative breast cancers 
(TNBCs). DNA was extracted from microdissected formalin-fixed paraffin-embedded 
sections of tumor and normal tissue from two pure and six mixed breast ACCs. Each tumor 
component of the mixed cases was microdissected separately. Tumor and normal samples 
were subjected to targeted capture massively parallel sequencing targeting all exons of 254 
genes, including genes most frequently mutated in breast cancer and related to DNA repair. 
Selected somatic mutations were validated by targeted amplicon resequencing and Sanger 
sequencing. Akin to other forms of TNBC, the most frequently mutated gene found in breast 
ACCs was TP53 (one pure and six mixed cases). Additional somatic mutations affecting 
breast cancer-related genes found in ACCs included PIK3CA, MTOR, CTNNB1, BRCA1, 
ERBB4, ERBB3, INPP4B and FGFR2. Copy number alteration analysis revealed complex 
patterns of gains and losses similar to those of TNBCs. Of the mixed cases analyzed, 
identical somatic mutations were found in the acinic and the high-grade non-acinic 
components in two out of four cases analyzed, providing evidence of their clonal 
relatedness. In conclusion, breast ACCs display the hallmark somatic genetic alterations 
found in high-grade forms of TNBC, including complex patterns of gene copy number 
alterations and recurrent TP53 mutations. Furthermore, we provide circumstantial genetic 
evidence to suggest that ACCs may constitute the substrate for the development of more 
aggressive forms of triple-negative disease. 
 
Keywords: massively parallel sequencing, immunohistochemistry, triple-negative, breast 
cancer, TP53 
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INTRODUCTION 
Acinic cell carcinoma (ACC) is a vanishingly rare special histologic type of breast cancer, 
included in the spectrum of salivary gland-type tumors of the breast. This group comprises 
benign and malignant entities that bear histologic resemblance to their salivary gland 
counterparts [1]. ACC of the breast is defined as a malignant neoplasm similar to the ACCs 
of the parotid, showing serous acinar differentiation with zymogen-type cytoplasmic granules 
[2]. Morphologically, breast ACCs are characterized by infiltrative microglandular or solid-
nest structures composed of cells with round-to-ovoid nuclei, discrete nucleoli and abundant 
eosinophilic-to-amphophilic cytoplasm containing small or coarse Paneth cell-like granules. 
Areas composed of clear cells with hypernephroid appearance can be present [3]. 
Immunohistochemical analyses of these cancers have revealed expression of S100-protein, 
epithelial membrane antigen (EMA) and serous differentiation markers, including amylase, 
lysozyme and alpha 1-antichymotrypsin [4]. Like many salivary gland-type tumors of the 
breast, ACCs display a triple-negative phenotype (that is, estrogen receptor (ER)-negative, 
progesterone receptor (PR)-negative and HER2-negative) [3].  
 
Since its first description in 1996 [5], only thirty-nine cases of ACCs have been described in 
the breast, usually as case reports or small case series (reviewed in [4]). Distant recurrences 
have been described, but these are rare and usually related to the presence of a poorly 
differentiated invasive component [6-8]. Therefore, in contrast to the majority of triple-
negative breast cancers (TNBCs) that show an overall aggressive clinical behavior, breast 
ACC is considered to be a favorable prognosis tumor [1,4,9].  
 
There is burgeoning evidence to demonstrate that TNBC is an operational term that 
encompasses a heterogeneous collection of entities with distinct clinical behaviors and 
pathologic characteristics [10,11]. As a group, the majority of TNBCs are high-grade invasive 
ductal carcinomas of no special type, which display an aggressive clinical behavior, high 
response rates to conventional chemotherapy regimens and high levels of genetic instability 
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[10-13]. Massively parallel sequencing studies have revealed that, as a group, high-grade 
TNBCs are characterized by high numbers of somatic mutations, with TP53 (82%) and 
PIK3CA (10%) being the most frequently mutated genes; however, a great deal of 
heterogeneity has been documented, with some tumors displaying over 200 somatic 
mutations affecting protein coding genes, whereas others display one or two somatic 
mutations [12,13].  
 
Despite their triple-negative phenotype, salivary gland-type tumors of the breast often have 
genomic features that are distinct from those of high-grade TNBCs [10,14-17]. Secretory 
carcinoma and adenoid cystic carcinoma of the breast, as their salivary gland counterparts, 
are characterized by recurrent chromosomal translocations that result in specific fusion 
genes (ETV6-NTRK3 and MYB-NFIB, respectively) [18-21]. Furthermore, breast adenoid 
cystic carcinomas display low levels of chromosomal instability and fewer copy number 
alterations than high-grade TNBCs, and patterns of somatic genetic alterations distinct from 
those of low-grade invasive ductal carcinomas [14,20,22]. A recent case report 
demonstrated that breast ACCs may develop in the context of BRCA1 germline mutation 
carriers; genetic analysis of one such case revealed loss of heterozygosity (LOH) of the 
BRCA1 locus and the presence of a TP53 somatic mutation, akin to other types of BRCA1-
related breast cancers [23]. Our group has recently demonstrated by Sanger sequencing 
analysis that, like common types of TNBC, TP53 mutations are found in up to 80% of breast 
ACCs [24].  
 
Here we sought to define whether breast ACCs are underpinned by somatic genetic 
alterations affecting the genes most frequently mutated in breast cancer and DNA repair 
related genes, as these tumors may arise in the context of BRCA1 germline mutations. 
Given that a subset of ACCs of the breast are found in association with high-grade TNBCs, 
we investigated whether ACCs might constitute the substrate for the development of a more 
aggressive form of triple-negative disease. 
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MATERIALS AND METHODS 
Cases and Immunohistochemistry 
 
Seven cases with a diagnosis of ACC of the breast were obtained from the consultation files 
of one of the authors (IOE) and one case from the pathology archives of Vall d'Hebron 
University Hospital, Barcelona, Spain. Histologic and immunohistochemical details of the 
cases included in this study are reported elsewhere [24]. All cases were reviewed by four of 
the authors (ZH, EAR, IOE and JSR-F), and classified as pure ACCs (n=2) and mixed ACCs 
(n=6; Table 1). The samples were anonymized prior to analysis. This study was approved by 
the local ethics committees from the contributing institutions. Patient consents were obtained 
if required by the protocols approved. Hematoxylin and eosin-stained sections of each case 
were further reviewed by four pathologists (EGR, AMS, CM and JSR-F), who analyzed the 
morphologic features of each component in detail following previously described criteria [3]. 
In addition, the presence of invasive components of different histologic types and their 
histologic characteristics were assessed. Each tumor component was graded separately 
according to the Nottingham grading system[25]. Immunohistochemical analysis was 
performed on representative formalin-fixed paraffin embedded (FFPE) sections of each 
sample using validated antibodies against ER, PR, HER2, lysozyme, Ki67 and p53. Details 
and scoring systems are available in the Supplementary Methods. 
 
Microdissection and DNA extraction 
Eight-µm-thick sections of representative FFPE blocks of the tumor and normal breast tissue 
from each case were stained with nuclear fast red and microdissected using a sterile needle 
under a stereomicroscope (Olympus SZ61) to ensure >80% of tumor cell content and that 
the normal tissue was devoid of any neoplastic cells as previously described [26,27]. 
Morphologically distinct components of each mixed ACC (i.e. acinic and non-acinic 
components) were microdissected separately [27]. Genomic DNA was extracted from each 
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tumor component and matched normal tissue using the DNeasy Blood and Tissue Kit 
(Qiagen) and quantified using the Qubit Fluorometer assay (Life Technologies) as previously 
described[28]. 
 
Targeted capture massively parallel sequencing 
Sufficient DNA was obtained from normal and tumor samples from two pure ACCs, six acinic 
components of mixed cases, from which DNA could also be obtained from the non-acinic 
components in four cases. Normal and tumor DNA samples were subjected to targeted 
capture massively parallel sequencing at the Integrated Genomics Operation (IGO), 
Memorial Sloan Kettering Cancer Center, using a customized breast cancer panel targeting 
all exons of 254 genes recurrently mutated in breast cancer and DNA repair-related genes 
(Supplementary Table S1) using custom oligonucleotides (NimblegenSeqCap) as previously 
described [26,29]. Massively parallel sequencing reads were aligned to the human reference 
genome hg19 using the Burrows-Wheeler Aligner [30]. Local realignment, duplicate removal 
and quality score recalibration were performed using the Genome Analysis Toolkit [31]. 
Somatic single nucleotide variants (SNVs) were identified using MuTect [32]; small insertions 
and deletions (indels) were identified using Strelka and VarScan 2 [33,34] and further 
curated by manual inspection. SNVs and indels with mutant allelic fraction of <1% and/or 
supported by <5 reads were disregarded [35]. All mutations identified by targeted capture 
sequencing were subsequently subjected to validation using a targeted amplicon sequencing 
approach (Supplementary Methods, Supplementary Table S2). In addition, selected 
mutations were validated by Sanger sequencing as previously described [28] 
(Supplementary Methods, Supplementary Table S3). ExomeCNV was employed to 
determine whether a gene harboring a somatic mutation was also targeted by LOH [36]; the 
loci of mutated genes were also manually curated to resolve potential LOH through the 
analysis of chromosomal copy number plots generated by VarScan 2 [33]. Copy number 
variations were analyzed using VarScan 2 [33] and segmentation was performed as 
previously described (Supplementary Methods) [37]. Targeted capture massively parallel 
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sequencing data have been deposited in the Sequence Read Archive (SRA) under 
accession number SRP052551. 
 
The potential functional effect of each SNV was investigated using a combination of 
MutationTaster [38] and CHASM [39]. The mutations identified as non-
deleterious/passengers by both computational prediction algorithms were considered 
passenger alterations [40]. Genes affected by non-passenger mutations were further 
annotated according to their presence in three cancer gene datasets, Kandoth et al. [41], the 
Cancer Gene Census [42] and Lawrence et al. [43]. Cancer cell fractions were defined using 
ABSOLUTE [44] and clonal composition analysis was carried out using SubcloneSeeker [45] 
(Supplementary Methods). 
 
RESULTS 
ACCs are low-grade TNBCs 
The pure ACCs and the ACC components of all mixed cases included in this study displayed 
the cardinal histologic features of breast ACCs, including infiltrating microglandular growth 
pattern and the presence of cytoplasmic secretory granules (Figures 1 and 2, Table 2). The 
two pure ACCs were of grades 1 and 2. The ACC components of the mixed cases were of 
grade 1 and 2 in four and three cases, respectively (Table 2), whereas the non-acinic 
components of mixed tumors included five grade 3 invasive ductal carcinomas of no special 
type (IDC-NST), one grade 2 IDC-NST and one grade 3 metaplastic carcinoma (Figure 2, 
Table 2).  Immunohistochemical analysis revealed that pure ACCs and the ACC components 
of the mixed cases displayed the characteristic triple-negative phenotype and 
immunoreactivity for lysozyme, a serous differentiation marker (Figures 1 and 2, Table 2). All 
non-ACC components tested showed a triple-negative immunohistochemical profile (Table 
2). 
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ACCs display a complex repertoire of mutations with recurrent TP53 somatic 
mutations 
Targeted capture massively parallel sequencing analysis yielded a median depth of 
coverage of 107x to 155x, 157x to 653x and 130x to 818x in pure ACCs (n=2), acinic 
components of mixed cases (n=6), and non-acinic components of mixed cases (n=4, Table 
2), respectively. Targeted amplicon resequencing analysis validated 133 of the 134 single 
nucleotide variants and indels identified at a median depth of coverage of 7,361x, 6,044x to 
7,745x and 6,876x to 7,448x in pure ACC (n=1), acinic components of mixed cases (n=6) 
and non-acinic components of mixed cases (n=4, Table 2), respectively (Supplementary 
Table S2). The two pure and six acinic components of mixed carcinomas displayed a 
median of 5 somatic mutations affecting the 254 genes tested (range 2 to 11, Table 2 and 
Supplementary Table S4). A re-analysis of the 78 TNBCs from The Cancer Genome Atlas 
(TCGA) breast cancer study revealed a median frequency of 3 somatic mutations (range 0 to 
13) affecting the exons of the 254 genes included in our targeted panel [12], suggesting that 
there was a higher number of mutations affecting these 254 genes in ACCs than in the 
TNBCs analyzed by TCGA (Wilcoxon test, p=0.003). Although these differences may reflect 
the biology of ACCs, it is equally plausible that they may stem from the fact that in our study, 
cases were microdissected and sequencing depth was substantially higher than that of 
cases analyzed by TCGA.  
 
TP53 was the most commonly mutated gene, being present in seven acinic cell components 
(one of two pure ACCs, and in six ACC components of mixed cases; Figure 3). It should be 
noted that the TP53 wild-type ACCs displayed histologic features similar to the TP53 mutant 
cases included in this study.  Additional recurrently mutated genes included lysine (K)-
specific methyltransferase 2D (KMT2D, also known as MLL2), v-erb-b2 avian erythroblastic 
leukemia viral oncogene homolog 4 (ERBB4) and nebulin (NEB, Figure 3). Other non-
synonymous somatic mutations affecting genes frequently mutated in breast cancer found in 
ACCs included  phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha 
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(PIK3CA),  mechanistic target of rapamycin (MTOR), β-catenin (CTNNB1),  breast cancer 1 
early onset (BRCA1), v-Erb-B2 avian erythroblastic leukemia viral oncogene homolog 3 
(ERBB3), inositol polyphosphate-4-phosphatase type II (INPP4B) and fibroblast growth 
factor receptor 2 (FGFR2). The truncating BRCA1 somatic mutation identified in case 17 
was coupled with LOH of the wild-type allele (Figure 3) providing evidence of complete loss 
of BRCA1. Given this observation and the fact that an ACC has been reported in a patient 
with a BRCA1 germline mutation [23], we investigated whether the patients included in this 
study harbored germline disease-causing mutations affecting DNA-repair related breast 
cancer susceptibility genes, including BRCA1, BRCA2, PALB2, RAD51C, RAD51D, BRIP1 
and FAM175A. This analysis revealed the presence of a germline frame-shift mutation of 
BRCA1 (E23*) in case 10. In this case, somatic LOH of the BRCA1 wild-type allele was 
observed (Supplementary Figure S1). 
 
Sanger sequencing analysis of selected mutations confirmed the TP53, PIK3CA, KMT2D, 
ERBB4 and NEB somatic mutations (Supplementary Figure S2). Furthermore, 
immunohistochemical analysis of p53 revealed strong nuclear expression in the cases 
harboring a TP53 missense mutation; cases 15 and 17, which harbored TP53 frameshift 
mutations coupled with LOH of the wild-type allele, lacked p53 expression, consistent with 
the type of TP53 somatic genetic alteration found (Table 2).  
 
In cases 14 and 16, the two morphologically distinct ACC components were successfully 
sequenced and were shown to harbor somatic mutations in common. In case 14, two 
identical somatic mutations were found in the grade 1 and grade 2 ACC components (i.e. 
TP53 R273C and INPP4B Q306K); however, two and four somatic mutations were restricted 
to the grade 1 and grade 2 components, respectively (Figure 4). Interestingly, distinct 
somatic mutations targeting the cubulin (CUBN) gene were found in each component, 
suggestive of a potential convergent phenotype. In case 16, the microglandular and clear 
cell hypernephroid ACC components shared seven identical somatic mutations, including a 
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TP53 V157D and a hotspot PIK3CA E542K mutations (Figure 4); however, the 
microglandular ACC component harbored four additional somatic mutations not identified in 
the clear cell component, including an ERBB3 M60R somatic mutation. Evidence of a 
potential convergent phenotype was also observed in this case, given that the 
microglandular component harbored a CTNNB1 N387K mutation, whereas the clear cell 
component harbored a CTNNB1 K335T mutation (Figure 4). 
 
ACCs of the breast display complex patterns of gene copy number alterations 
Consistent with the presence of TP53 somatic mutations, gene copy number analysis 
revealed that ACCs displayed complex patterns of copy number alterations, with multiple 
gains and losses across the entire genome. Recurrent changes included gains of 1q, 2q, 8q 
and losses of 3p, 5q, 12q, 13q, 14q, 17p and 17q (Supplementary Figure S3). Furthermore, 
the ACC components of cases 7 and 10 displayed amplification of the 1q43 region involving 
the v-akt murine thymoma viral oncogene homolog 3 (AKT3) and formin 2 (FMN2) gene loci 
(Supplementary Figure S1 and Supplementary Table S5). The 8q24.12 locus was amplified 
in the ACC component of cases 9 and 14, encompassing the DEP domain containing 
MTOR-interacting protein (DEPTOR) gene locus, and the 8q24.3 locus was amplified in the 
ACC component of cases 9 and 17, encompassing the focal adhesion kinase, protein 
tyrosine kinase 2 (PTK2) gene (Figures 4 and 5, Supplementary Figure S1, Supplementary 
Table S5). Furthermore, we identified a homozygous deletion involving the AHNAK 
nucleoprotein 2 (AHNAK2) gene in the ACC of case 10 (Supplementary Figure S1, 
Supplementary Table S5).  
 
Genomic profiles of acinic and non-acinic cell components of mixed ACCs  
Massively parallel sequencing results were available for both the acinic and non-acinic 
components of four mixed cases, including three grade 3 invasive ductal carcinomas of no 
special type and one grade 3 metaplastic carcinoma (Table 2). The ACC and the high-grade 
TNBC components were found to be clonally related in two cases based on the mutational 
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and copy number profiling (cases 9 and 16, Figures 4, 5 and 6; Supplementary Tables S4 
and S5). Additional somatic mutations were found in the high-grade triple-negative 
carcinoma component of case 9, including a clonal PIK3CA E542K hotspot mutation, 
followed by a subclonal frame-shift mutation affecting the bona fide cancer gene KMT2D and 
a subclonal missense mutation affecting the AK9 gene (Figures 5 and 6). In case 16, 
somatic mutations affecting ERBB3, NEB and CTNNB1 N387K were identified only in the 
ACC component. On close inspection, a progression from the classic ACC to the clear cell 
hypernephroid component to the metaplastic carcinoma could be observed in case 16 on the 
basis of the patterns of mutations and gene copy number alterations. A somatic CTNNB1 
K335T mutation and a focal amplification of 5p13.1-p12, encompassing the loci of the growth 
hormone receptor gene (GHR) and the rapamycin-insensitive companion of mTOR gene 
(RICTOR) were only present in the clear cell and in the metaplastic carcinoma components 
(Figures 4 and 6, Supplementary Table S5).  
 
No shared somatic mutations were detected in the ACC and the high-grade triple-negative 
carcinoma components of cases 14 and 15 (Figures 4 and 5); the components of these 
cases also displayed distinct copy number profiles (Figures 4 and 5). The invasive 
component of case 14 harbored a 9p24.2-21.3 amplification and a homozygous deletion 
involving the retinoblastoma (RB1) gene locus (Figure 4 and Supplementary Table S5). In 
case 15, we identified a homozygous deletion in 14q21.2 encompassing the Fanconi 
anemia, complementation group M (FANCM) gene restricted to the invasive component 
(Figure 4 and Supplementary Table S5).  
 
Taken together, our results provide circumstantial genetic evidence to suggest that, in some 
cases, ACCs may constitute the substrate for the development of invasive TNBCs of higher 
histologic grade or of more aggressive subtypes.  
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DISCUSSION 
Here we demonstrate that breast ACCs harbor a high mutational burden, recurrent TP53 
mutations, BRCA1 germline and somatic pathogenic mutations, and complex patterns of 
gene copy number alterations, in a way akin to high-grade TNBCs. Our findings corroborate 
the notion that TNBCs constitute a heterogeneous collection of diseases[10,11] with varying 
morphologic and molecular characteristics and clinical behaviors, whose unifying 
characteristics include the lack of ER, PR and HER2 expression and recurrent TP53 somatic 
mutations [12,13]. The pattern of TP53 mutations found in TNBCs differs from that observed 
in ER-positive tumors, with an enrichment for nonsense SNVs and indels [12,13]. The 
frequency of somatic TP53 mutations found in breast ACCs is similar to that of high-grade 
TNBCs (87% vs 82%, respectively); in contrast, however, ACCs preferentially harbored 
missense mutations, including mutations affecting the R273 hotspot found in three ACCs 
(cases 7, 10 and 14). Additional mutations and amplifications found in breast ACCs involved 
genes or pathways that have been previously reported to be altered, although some at low 
frequency, in high-grade TNBCs, including PIK3CA, FGFR2, INPP4B, ERBB4, AKT3, FMN2, 
DEPTOR and PTK2 according to a reanalysis of the breast TCGA data (www.cbioportal.org; 
accessed 01-15-2015) [12,46]. TNBCs often display high levels of genomic instability that 
result in multiple low-level gains and losses throughout the genome, with a few high-level 
amplifications [47]. Our results reveal a similar complexity in the pattern of gains and losses 
across the entire genome of the ACCs, including recurrent copy number alterations in 
regions often altered in other forms of triple-negative disease, such as 8q gain and 5q loss 
[12,47,48]. Finally, consistent with the notions that i) BRCA1 germline mutations 
preferentially predispose to the development of breast cancers with a triple-negative 
phenotype [11] and ii) 11%-16% of TNBCs harbor BRCA1 germline or somatic mutations 
[49-51], one of the pure ACCs analyzed displayed a BRCA1 nonsense somatic mutation 
coupled with LOH of the BRCA1 wild-type allele and a somatic TP53 mutation, and another 
mixed ACC harbored a germline BRCA1 mutation coupled with somatic LOH of the wild-type 
allele and a TP53 somatic mutation. This finding suggests that the presence of TP53 and 
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BRCA1 loss-of-function may not be sufficient for the development of high-grade TNBCs. In 
fact, conditional mouse models of BRCA1 and TP53 have been shown to result in the 
development of rather heterogeneous tumors; although the majority of lesions are of high 
histologic grade and display the cardinal features of human high-grade TNBCs, 4% to 31% 
of the mammary gland tumors those animals developed were of grades 1 or 2 [52,53]. 
Ingenuity Pathway Analysis employing genes mutated in pure and/ or mixed ACCs and in 
common forms of TNBCs from TCGA revealed a significant enrichment for genes related to 
cellular growth and proliferation and cell development in both datasets (score 37 and 38 
respectively; Supplementary Figure S4). By contrast, a significant enrichment for genes 
related to DNA recombination and repair processes was only found in TNBCs (score 51, 
Supplementary Figure S4) but not in ACCs. Taken together, our findings support the 
contention that, despite its reported indolent clinical behavior, breast ACCs are closely 
related to the common forms of high-grade TNBC but display a relatively more limited 
genomic complexity. It is plausible that the differences in clinical behavior between ACCs 
and common forms of triple-negative disease stem from the lower proliferation rates, as 
defined by Ki67, and histologic grades found in ACCs than in common forms of TNBCs 
(Table 2).  
 
The presence of poorly differentiated tumors adjacent to ACCs is not an uncommon finding 
in the breast [7,23] and it has also been reported in the context of ACCs of the salivary 
glands [54]. The non-ACC components of the mixed cases included in this study were all 
high-grade, highly proliferative triple-negative breast carcinomas (Figure 2 and Table 2). Our 
analyses revealed identical somatic mutations and similar patterns of copy number 
alterations in the ACC and the high-grade triple-negative carcinoma components of two of 
the four cases. In both cases, a higher degree of genomic complexity was observed in the 
high-grade lesion; in one of the cases, a clear stepwise increase in the genomic complexity 
from the microglandular ACC component to the clear cell ACC component to the metaplastic 
carcinoma component was observed (Figure 4). In this case, whilst the microglandular ACC 
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component displayed a CTNNB1 N387K mutation, the clear cell ACC and the metaplastic 
carcinoma components harbored a CTNNB1 K335T mutation, suggesting a convergent 
phenotype and a potential progression mechanism. These findings provide direct evidence 
that in some cases, classic ACCs are an indolent form of triple-negative disease that may 
constitute the substrate for the development of high-grade TNBCs. 
 
In the two cases of ACCs associated with high-grade TNBCs that displayed distinct 
constellations of somatic mutations and gene copy number alterations (cases 14 and 15; 
Figures 4 and 5), TP53 mutations were found to be restricted to the ACC component and 
massively parallel sequencing and Sanger sequencing failed to identify TP53 mutations in 
the high-grade triple-negative carcinoma components of these cases. Potential alternative 
driver genetic alterations found in these components included a RAD50 homolog (RAD50) 
gene S560R mutation coupled with LOH of the wild-type allele in case 14, and a core-
binding factor, beta subunit (CBFB) gene truncating mutation in case 15 (Figures 4 and 5). 
Although no somatic mutations and gene copy number alterations were found in common 
between the acinic and high-grade triple-negative components of these cases, a finding that 
could be interpreted as suggestive of a non-clonal origin of these lesions, we cannot rule out 
a potential common origin on the basis of genetic alterations not surveyed in this study. 
 
This study has several limitations. First, given the rarity of breast ACCs, the sample size of 
our study is relatively small, in particular of pure ACCs (n=2). It should be noted, however, 
that this study represents the largest cohort of breast ACCs subjected to massively parallel 
sequencing analysis to date. Second, given that all cases were formalin-fixed, paraffin-
embedded and that the lesions were rather small, we were only able to subject these 
samples to targeted capture massively parallel sequencing. Therefore, we cannot rule out 
the presence of a pathognomonic mutation or fusion gene affecting a gene not included in 
this study that might define ACCs of the breast. This is, however, unlikely, given that breast 
and salivary gland tumors driven by highly recurrent pathognomonic fusion genes or 
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mutations often lack TP53 mutations and have simple patterns of gene copy number 
alterations (e.g. adenoid cystic carcinomas of the breast[ 20] and polymorphous low-grade 
adenocarcinomas [28]). Our findings, however, warrant further investigation of the repertoire 
of somatic mutations and expressed fusion genes in breast ACCs. Finally, given the 
retrospective nature of this study and the fact that most samples were obtained from the 
consultation files of one of the authors, we were unable to perform a detailed survival 
analysis. 
 
In conclusion, ACCs of the breast are part of the spectrum of TNBCs and despite their low-
grade and reported indolent clinical behavior, these tumors display the cardinal genomic 
features documented in high-grade forms of triple-negative disease. We have also provided 
circumstantial data to suggest that, the ACC may constitute the substrate for the 
development of a high-grade TNBC in a subset of cases, given the presence of identical 
truncal/ clonal mutations present in both the ACC and the high-grade TNBC. Finally, our 
observations reiterate the fact that TNBC is a mere operational term [11] and that 
histopathologic analysis provides important information about the biology and clinical 
behavior of TNBCs. 
 
ACKNOWLEDGMENTS 
SP is funded by a Susan G Komen Postdoctoral Fellowship Grant (PDF14298348), AMS by 
a stipend from the German Cancer Aid (Dr. Mildred Scheel Stiftung), and CM by AIRC 
(MFAG13310). 
 
AUTHORS CONTRIBUTIONS 
JSR-F, BW and IOE conceived and supervised the study. IOE, ZH, EAR and LDM-A 
provided the samples; EGR, AMS, CM, NF, ME, ZH, EAR, IOE and JSR-F performed the 
histological review. EGR, AMS, CM and NF performed the sample microdissection; EGR, 
SP, ACP, MRF, LGM, AAJ and CKYN carried out experiments and analyzed data; EGR, SP, 
This article is protected by copyright. All rights reserved 
CKYN, BW and JSR-F interpreted results and drafted the manuscript. All authors reviewed 
and approved the final version of the manuscript. 
  
This article is protected by copyright. All rights reserved 
REFERENCES 
1. Foschini MP, Krausz T. Salivary gland-type tumors of the breast: a spectrum of 
benign and malignant tumors including "triple negative carcinomas" of low malignant 
potential. Semin Diagn Pathol 2010; 27: 77-90. 
2. Lakhani SR, Ellis IO, Schnitt SJ, et al. WHO classification of tumours of the breast. 
(4th ed). IARC Press: Lyon, 2012. 
3. Damiani S, Pasquinelli G, Lamovec J, et al. Acinic cell carcinoma of the breast: an 
immunohistochemical and ultrastructural study. Virchows Arch 2000; 437: 74-81. 
4. Limite G, Di Micco R, Esposito E, et al. Acinic cell carcinoma of the breast: Review of 
the literature. Int J Surg 2014; 12S1: S35-S39. 
5. Roncaroli F, Lamovec J, Zidar A, et al. Acinic cell-like carcinoma of the breast. 
Virchows Arch 1996; 429: 69-74. 
6. Coyne JD, Dervan PA. Primary acinic cell carcinoma of the breast. J Clin Pathol 
2002; 55: 545-547. 
7. Peintinger F, Leibl S, Reitsamer R, et al. Primary acinic cell carcinoma of the breast: 
a case report with long-term follow-up and review of the literature. In: Histopathology. 
(ed)^(eds): England, 2004; 645-648. 
8. Huo L, Bell D, Qiu H, et al. Paneth cell-like eosinophilic cytoplasmic granules in 
breast carcinoma. Ann Diagn Pathol 2011; 15: 84-92. 
9. Pia-Foschini M, Reis-Filho JS, Eusebi V, et al. Salivary gland-like tumours of the 
breast: surgical and molecular pathology. J Clin Pathol 2003; 56: 497-506. 
10. Turner NC, Reis-Filho JS. Tackling the diversity of triple-negative breast cancer. Clin 
Cancer Res 2013; 19: 6380-6388. 
11. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 
2010; 363: 1938-1948. 
12. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast 
tumours. Nature 2012; 490: 61-70. 
13. Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of 
primary triple-negative breast cancers. Nature 2012; 486: 395-399. 
14. Horlings HM, Weigelt B, Anderson EM, et al. Genomic profiling of histological special 
types of breast cancer. Breast Cancer Res Treat 2013; 142: 257-269. 
15. Weigelt B, Geyer FC, Reis-Filho JS. Histological types of breast cancer: how special 
are they? Mol Oncol 2010; 4: 192-208. 
16. Weigelt B, Horlings HM, Kreike B, et al. Refinement of breast cancer classification by 
molecular characterization of histological special types. J Pathol 2008; 216: 141-150. 
This article is protected by copyright. All rights reserved 
17. Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there 
a unifying taxonomy? Nat Rev Clin Oncol 2009; 6: 718-730. 
18. Tognon C, Knezevich SR, Huntsman D, et al. Expression of the ETV6-NTRK3 gene 
fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2002; 2: 
367-376. 
19. Persson M, Andren Y, Mark J, et al. Recurrent fusion of MYB and NFIB transcription 
factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci U S 
A 2009; 106: 18740-18744. 
20. Wetterskog D, Lopez-Garcia MA, Lambros MB, et al. Adenoid cystic carcinomas 
constitute a genomically distinct subgroup of triple-negative and basal-like breast 
cancers. J Pathol 2012; 226: 84-96. 
21. Lae M, Freneaux P, Sastre-Garau X, et al. Secretory breast carcinomas with ETV6-
NTRK3 fusion gene belong to the basal-like carcinoma spectrum. Mod Pathol 2009; 
22: 291-298. 
22. Wetterskog D, Wilkerson PM, Rodrigues DN, et al. Mutation profiling of adenoid 
cystic carcinomas from multiple anatomical sites identifies mutations in the RAS 
pathway, but no KIT mutations. Histopathology 2013; 62: 543-550. 
23. Ripamonti CB, Colombo M, Mondini P, et al. First description of an acinic cell 
carcinoma of the breast in a BRCA1 mutation carrier: a case report. BMC Cancer 
2013; 13: 46. 
24. Piscuoglio S, Hodi Z, Katabi N, et al. Are acinic cell carcinomas of the breast and 
salivary glands distinct diseases? Histopathology 2015. 
25. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of 
histological grade in breast cancer: experience from a large study with long-term 
follow-up. Histopathology 1991; 19: 403-410. 
26. Natrajan R, Wilkerson PM, Marchiò C, et al. Characterization of the genomic features 
and expressed fusion genes in micropapillary carcinomas of the breast. J Pathol 
2014; 232: 553-565. 
27. Geyer FC, Lacroix-Triki M, Colombo PE, et al. Molecular evidence in support of the 
neoplastic and precursor nature of microglandular adenosis. Histopathology 2012; 
60: E115-130. 
28. Weinreb I, Piscuoglio S, Martelotto LG, et al. Hotspot activating PRKD1 somatic 
mutations in polymorphous low-grade adenocarcinomas of the salivary glands. Nat 
Genet 2014; 46: 1166-1169. 
29. Cheng DT, Mitchell TN, Zehir A, et al. Memorial Sloan Kettering-Integrated Mutation 
Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-
This article is protected by copyright. All rights reserved 
Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular 
Oncology. J Mol Diagn 2015; 17: 251-264. 
30. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler 
transform. Bioinformatics 2009; 25: 1754-1760. 
31. McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a MapReduce 
framework for analyzing next-generation DNA sequencing data. Genome Res 2010; 
20: 1297-1303. 
32. Cibulskis K, Lawrence MS, Carter SL, et al. Sensitive detection of somatic point 
mutations in impure and heterogeneous cancer samples. Nat Biotechnol 2013; 31: 
213-219. 
33. Koboldt DC, Zhang Q, Larson DE, et al. VarScan 2: somatic mutation and copy 
number alteration discovery in cancer by exome sequencing. Genome Res 2012; 22: 
568-576. 
34. Saunders CT, Wong WS, Swamy S, et al. Strelka: accurate somatic small-variant 
calling from sequenced tumor-normal sample pairs. Bioinformatics 2012; 28: 1811-
1817. 
35. De Mattos-Arruda L, Weigelt B, Cortes J, et al. Capturing intra-tumor genetic 
heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a 
proof-of-principle. Ann Oncol 2014; 25: 1729-1735. 
36. Sathirapongsasuti JF, Lee H, Horst BA, et al. Exome sequencing-based copy-
number variation and loss of heterozygosity detection: ExomeCNV. Bioinformatics 
2011; 27: 2648-2654. 
37. De Mattos-Arruda L, Bidard FC, Won HH, et al. Establishing the origin of metastatic 
deposits in the setting of multiple primary malignancies: the role of massively parallel 
sequencing. Mol Oncol 2014; 8: 150-158. 
38. Schwarz JM, Rodelsperger C, Schuelke M, et al. MutationTaster evaluates disease-
causing potential of sequence alterations. Nat Methods 2010; 7: 575-576. 
39. Carter H, Chen S, Isik L, et al. Cancer-specific high-throughput annotation of somatic 
mutations: computational prediction of driver missense mutations. Cancer Res 2009; 
69: 6660-6667. 
40. Martelotto LG, Ng C, De Filippo MR, et al. Benchmarking mutation effect prediction 
algorithms using functionally validated cancer-related missense mutations. Genome 
Biol 2014; 15: 484. 
41. Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance 
across 12 major cancer types. Nature 2013; 502: 333-339. 
42. Futreal PA, Coin L, Marshall M, et al. A census of human cancer genes. Nat Rev 
Cancer 2004; 4: 177-183. 
This article is protected by copyright. All rights reserved 
43. Lawrence MS, Stojanov P, Mermel CH, et al. Discovery and saturation analysis of 
cancer genes across 21 tumour types. Nature 2014; 505: 495-501. 
44. Carter SL, Cibulskis K, Helman E, et al. Absolute quantification of somatic DNA 
alterations in human cancer. Nat Biotechnol 2012; 30: 413-421. 
45. Qiao Y, Quinlan AR, Jazaeri AA, et al. SubcloneSeeker: a computational framework 
for reconstructing tumor clone structure for cancer variant interpretation and 
prioritization. Genome Biol 2014; 15: 443. 
46. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer 
genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6: pl1. 
47. Turner N, Lambros MB, Horlings HM, et al. Integrative molecular profiling of triple 
negative breast cancers identifies amplicon drivers and potential therapeutic targets. 
Oncogene 2010; 29: 2013-2023. 
48. Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 
2,000 breast tumours reveals novel subgroups. Nature 2012; 486: 346-352. 
49. Gonzalez-Angulo AM, Timms KM, Liu S, et al. Incidence and outcome of BRCA 
mutations in unselected patients with triple receptor-negative breast cancer. Clin 
Cancer Res 2011; 17: 1082-1089. 
50. Young SR, Pilarski RT, Donenberg T, et al. The prevalence of BRCA1 mutations 
among young women with triple-negative breast cancer. BMC Cancer 2009; 9: 86. 
51. Fostira F, Tsitlaidou M, Papadimitriou C, et al. Prevalence of BRCA1 mutations 
among 403 women with triple-negative breast cancer: implications for genetic 
screening selection criteria: a Hellenic Cooperative Oncology Group Study. Breast 
Cancer Res Treat 2012; 134: 353-362. 
52. Molyneux G, Geyer FC, Magnay FA, et al. BRCA1 basal-like breast cancers originate 
from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 
2010; 7: 403-417. 
53. Liu X, Holstege H, van der Gulden H, et al. Somatic loss of BRCA1 and p53 in mice 
induces mammary tumors with features of human BRCA1-mutated basal-like breast 
cancer. Proc Natl Acad Sci U S A 2007; 104: 12111-12116. 
54. Skálová A, Sima R, Vanecek T, et al. Acinic cell carcinoma with high-grade 
transformation: a report of 9 cases with immunohistochemical study and analysis of 
TP53 and HER-2/neu genes. Am J Surg Pathol 2009; 33: 1137-1145. 
This article is protected by copyright. All rights reserved 
TABLES 
Table 1: Clinico-pathologic features of the acinic cell carcinomas included in this 
study. 
Case 
Age at 
diagnosis 
(years) 
Tumor 
size 
(mm) 
Node 
status 
Follow-up 
(months) 
Follow-up 
(status) 
Diagnosis 
7 36 50 10/17 24 DOD 
mixed IDC-NST 
and ACC 
9 55 19 0/8 132 DF 
mixed IDC-NST 
and ACC 
10 34 NA NA NA NA 
mixed IDC-NST 
and ACC 
12 42 NA NA NA NA pure ACC 
14 34 36 0/3 15 DF 
mixed IDC-NST 
and ACC 
15 48 20 NA 60 DF 
mixed IDC-NST 
and ACC 
16 70 NA NA NA DR 
mixed metaplastic 
carcinoma and 
ACC 
17 35 NA 2/22 72 DR pure ACC 
 
ACC, acinic cell carcinoma; DOD, dead of disease; DF, disease free; DR, disease 
recurrence; IDC-NST, invasive ductal carcinoma of no special type; NA, not available. 
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Table 2: Histologic and immunohistochemical features of the acinic cell carcinomas 
included in this study. 
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Each panel depicts representative micrographs of each component, its respective genome 
plot and repertoire of non-synonymous somatic mutations. In the genome plots, smoothed 
Log2 ratios were plotted on the y-axis according to their genomic positions indicated on the 
x-axis. Gains and losses are plotted in green and red, respectively. On the right, diagrams 
depicting the mutations identified in each component of each case. In these diagrams, each 
mutation is color-coded on the basis of its mutant allele fraction, as explained in the color 
key. A, case 14; B, case 16. Scale bars: 500µm. 
ACC: acinic cell carcinoma; CC: clear cell ACC component; G1, grade 1; G2, grade 2; IDC-
NST: invasive ductal carcinoma of no special type; MC: metaplastic carcinoma. 
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